ReprogrammingHuman study

ER-100

ER-100 is an OSK partial-reprogramming gene therapy in an open-label Phase 1 eye study. Its developer reports 56-day safety observations in three glaucoma patients and exploratory visual-field changes in two.

Life BiosciencesReviewed 24 Oct 20267 sources ↓

ER-100 is an experimental gene therapy for damaged retinal ganglion cells, the neurons that carry visual information from the eye toward the brain. Its first human study concerns open-angle glaucoma and non-arteritic anterior ischaemic optic neuropathy (NAION). The immediate research question is whether controlled expression of reprogramming factors can be tolerated in these cells and improve their function.

On 8 October 2026, Life Biosciences reported interim outcomes from three treated glaucoma participants followed through day 56. The company reported no dose-limiting toxicities or serious adverse events, and exploratory visual-field improvements in two people. A monitoring board recommended moving to the next dose.

These are very early, company-reported observations. With only three participants, no randomised control, short follow-up and variable visual tests, the presentation cannot show reliable restoration of vision or a reversal of general human ageing.

Illustrated eye cutaway with simplified retinal layers and an optic nerve leaving the back of the eye.
ER-100 targets retinal ganglion cells. Visual assessments test function alongside measurements of eye structure.
SchematicER-100: delivery, expression and observation
  1. AAV carries OSK instructionsOCT4, SOX2 and KLF4 are regulatory factors.
  2. Expression in retinal cellsThe experimental system controls expression with doxycycline.
  3. Observe safety and visionThe human study has its own design and endpoints.

This is the proposed mechanism and assessment chain; it shows no human efficacy result. Sources for this account.

The mechanism

OCT4, SOX2 and KLF4, collectively OSK, are transcription factors: proteins that help regulate which genes a cell expresses. ER-100 delivers instructions for OSK using a modified adeno-associated virus. The experimental system controls expression with doxycycline. It aims to change gene regulation in existing retinal cells.

The scientific foundation includes a 2020 mouse study in which OSK expression changed DNA methylation and gene expression, promoted axon regeneration after injury and improved visual function in glaucoma and ageing experiments. Those results connect reprogramming to tissue performance in an animal model. They do not establish how a human optic nerve will respond.

Life Biosciences subsequently reported nonhuman-primate experiments with an injury resembling NAION. Its 2024 conference disclosure described improvements in electrical-response and axon-density measurements. Conference and company reports require their own evidence label; the experimental particulars should be checked against a full report when available.

Human evidence

NCT07290244 plans to enrol up to 18 adults, with sequential glaucoma and NAION cohorts. The registry describes safety and tolerability as the principal purpose, with visual assessments and long-term monitoring. The record checked for this dossier listed no posted results. The estimate of primary completion is May 2027, followed by longer safety follow-up.

A trial beginning in a specific optic neuropathy does not establish treatment of ageing throughout the body. The local delivery, target cells and outcome measures define what this experiment can answer. An encouraging early observation would support further testing of this programme; a convincing claim about restoring vision will need the full data and an appropriate subsequent comparison.

The 8 October disclosure reports a dose of 2×10¹¹ vector genomes and daily doxycycline, with day-56 safety observations in three glaucoma participants. There were no reported dose-limiting toxicities, events of special interest or serious adverse events. The company reported improvements in visual-field measurements in two of the three. Those are uncontrolled exploratory findings, not posted trial-registry results or a peer-reviewed efficacy analysis.

Studies and experimental evidence

ER-100 Phase 1, NCT07290244

Design
Open-label, non-randomised sequential cohorts
Population or model
Adults with open-angle glaucoma or NAION
Sample size
18 planned; 3 glaucoma participants in the reported first cohort (day 56)
Comparison
Participant baseline; no randomised control
Duration
Initial assessments with follow-up planned to five years
Outcome
Safety, tolerability and exploratory visual measures

Company interim presentation reports short-term tolerability in three people and exploratory visual-field changes in two

Three participants, open label, no randomised comparator, short follow-up; source is company disclosure

Funding and interests: Sponsor: Life Biosciences

Reprogramming to recover youthful epigenetic information and restore vision

Design
Laboratory and mouse experiments
Population or model
Mouse retinal ganglion cells and optic-nerve disease/injury models
Sample size
Varies by experiment; not a single trial sample
Comparison
Experimental controls described in the paper
Duration
Varies by assay
Outcome
Methylation, gene expression, axon regeneration and visual function

OSK expression improved several molecular and functional measures in mice

Preclinical foundation; not a human ER-100 efficacy result

Funding and interests: Academic work; see paper for grant and commercial-interest disclosures

Nonhuman-primate ER-100 conference disclosure

Design
Preclinical injury-model experiments, company conference report
Population or model
Nonhuman primates with NAION-like injury
Sample size
Not reported in the checked disclosure
Comparison
Vehicle controls
Duration
Not fully reported in the checked disclosure
Outcome
Pattern electroretinogram and axon density

Company reported reduced functional and structural deficits

Source is a company summary of conference data; complete methods needed

Funding and interests: Life Biosciences programme

Development history

Unresolved questions

  • Will the next-dose cohort replicate the safety and visual-field findings with longer follow-up?
  • Do several visual assessments agree, and how do they relate to baseline variability?
  • Does the effect persist after OSK expression is switched off?
  • What ocular, immune or other adverse events appear with longer observation?
  • Which findings would justify a subsequent controlled efficacy study?

Further dose escalation, longer safety observation and a subsequent controlled study will determine whether early functional observations replicate. The interim company presentation is not proof of human rejuvenation.

Sources

  1. Trial registry · 19 May 2026ER-100 Phase 1: NCT07290244

    Sponsor-submitted record; planned design and completion dates, no posted results in checked record.

    Checked 4 Oct 2026
  2. Paper · 2 Dec 2020Reprogramming to recover youthful epigenetic information and restore vision

    Nature; DOI 10.1038/s41586-020-2975-4. Preclinical scientific foundation.

    Checked 4 Oct 2026
  3. Company disclosure · 21 Oct 2024Life Biosciences presents nonhuman-primate reprogramming data at AAO

    Conference findings summarised by the developer.

    Checked 4 Oct 2026
  4. Company disclosure · 28 Jan 2026Life Biosciences announces IND clearance for ER-100

    Primary source for company announcement; does not establish marketed approval.

    Checked 4 Oct 2026
  5. Company disclosure · 9 Jun 2026First patient dosed in ER-100 Phase 1

    Actual dosing announcement, separate from registry start date.

    Checked 4 Oct 2026
  6. Company disclosure · 1 Oct 2026ER-100 interim data presentation announced for Eyecelerator 2026

    Presentation scheduled for 8 October 2026; announcement contains no numerical clinical results.

    Checked 4 Oct 2026
  7. Company disclosure · 8 Oct 2026Life Biosciences announces first-in-human ER-100 Phase 1 data

    Three glaucoma participants, follow-up through day 56; safety and exploratory visual-field changes announced by developer, not a controlled efficacy demonstration.

    Checked 24 Oct 2026
Editorial responsibility

Dr T Smith, organic chemist and science educator. Review date: 24 Oct 2026. Corrections information.

Search the publication

Search programme histories and research articles.